Cash boost for UK bioprocessing
The private industry has been urged to join a public sector commitment fund in the UK to advance manufacturing R&D in bioprocessing, following the investment of approximately £9 million from two UK research councils.
The private industry has been urged to join a public sector commitment fund in the UK to advance manufacturing R&D in bioprocessing, following the investment of approximately £9 million from two UK research councils.
The amount, provided by the UK's Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Sciences Research Council (EPSRC), has been committed to the second phase of the public–private partnership Bioprocessing Research Industry Club: BRIC 2. The first phase of BRIC established a coherent bioprocessing community in the UK; the second phase aims to increase the numbers of trained bioprocessing professionals.
"The BRIC programme not only provides funds for projects that are relevant for all companies developing and manufacturing biological medicines, but also has produced a stream of researchers with the skills that are much needed by the UK bioprocessing sector," Mark Bustard, Head of bioprocessUK — which strongly supports the investment —said in a press statement. "This is a unique activity within the UK that we aim to build on to increase competitiveness and innovation in the development of biological medicines."
In a separate press statement issued by the BBSRC, Celia Caulcott, Director for Innovation and Skills, said: "We have been running the first phase of the partnership since 2005 when we committed to investing a combined total of £14 million. I am proud to say we have 17 bioprocessing companies in the club. BRIC 2 will build on early successes, but needs the commitment of both existing and new companies in the sector."
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
